RxDoctor Payments Data

Michael Weisberg, MD

Ophthalmology · Calumet City, ILNPI 1205097607

Payments from drug & device makers

$760in general payments, 2019–2025

Across 26 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$173
  • Johnson & Johnson Surgical Vision, Inc.$116
  • Johnson & Johnson Vision Care, Inc.$109
  • Aerie Pharmaceuticals, Inc.$77
  • Synergeyes, Inc.$65
  • Oyster Point Pharma, Inc.$55
  • plus $165 from 7 others

What the payments were for

  • Food & beverage$760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$760 in reported general payments places this provider in the 40th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$257,260
Medicare patients
606
Services billed
2,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$30,557
LumiganBimatoprost39$18,072
Prednisolone Acetate296$14,286
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$6,260
Ketorolac Tromethamine333$5,616
Latanoprost465$5,360
SimbrinzaBrinzolamide/Brimonidine Tart17$3,520
Gatifloxacin66$2,450
Fluorometholone25$2,379
Ofloxacin219$2,087
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat126$1,698
Brimonidine Tartrate56$1,111
Doxycycline Monohydrate36$680
Timolol Maleate79$657
Dorzolamide Hcl34$605

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$49$3,52017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Calumet City

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →